Claims for Patent: 9,540,410

Summary for Patent: 9,540,410

Title:	Gemcitabine prodrugs and uses thereof
Abstract:	The present invention provides compounds according to formula I: ##STR00001## and pharmaceutically acceptable salts thereof. For compounds of formula I, R.sup.1 and R.sup.2 are independently selected from the group consisting of H, --C(.dbd.O)--(CH.sub.2).sub.2-aryl, and --C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NH-aryl. The subscript n is from 2 to 6. R.sup.3 is selected from the group consisting of H and --C(.dbd.O)--O--R.sup.4; and R.sup.4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl. Compounds are provided wherein at least one of R.sup.1 and R.sup.2 is other than H. Pharmaceutical compositions, methods for inhibiting the growth of cancer cells, and methods for the treatment of cancer are also provided.
Inventor(s):	Wu; Laurence I. (Taipei, TW)
Assignee:	BOYEN THERAPEUTICS, INC. (Taipei, TW)
Application Number:	14/599,166
Patent Claims:	1. A method for treating cancer selected from the group consisting of pancreatic cancer, non-small cell lung cancer, breast cancer, ovarian cancer, bladder cancer, and colorectal cancer in a subject in need thereof by inhibiting the growth of cancer cells, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a compound according to formula I: ##STR00113## or a pharmaceutically acceptable salt thereof; wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of H, --C(.dbd.O)--(CH.sub.2).sub.2--Ar and --C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NH--Ar, and at least one of R.sup.1 and R.sup.2 is other than H, and Ar is aryl or heteroaryl; R.sup.3 is selected from the group consisting of H and --C(.dbd.O)--O--R.sup.4; R.sup.4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl; and the subscript n is an integer of from 2 to 6. 2. A method according to claim 1, wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of H, --C(.dbd.O)--(CH.sub.2).sub.2--Ar and --C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NH-phenyl, and at least one of R.sup.1 and R.sup.2 is other than H, and Ar is phenyl or 3-pyridyl; and the subscript n is 2, 4 or 6. 3. A method according to claim 1, wherein R.sup.2 and R.sup.3 are H. 4. A method according to claim 2, wherein R.sup.2 is H and R.sup.1 and R.sup.3 are other than H. 5. A method according to claim 2, wherein R.sup.1 is H and R.sup.2 and R.sup.3 are other than H. 6. A method according to claim 4, wherein R.sup.4 is selected from the group consisting of alkyl and substituted alkyl. 7. A method according to claim 5, wherein R.sup.4 is selected from the group consisting of alkyl and substituted alkyl. 8. A method according to claim 6, wherein R.sup.4 is C.sub.1-C.sub.8 alkyl. 9. A method according to claim 7, wherein R.sup.4 is C.sub.1-C.sub.8 alkyl. 10. A method according to claim 4, wherein R.sup.4 is C.sub.3-C.sub.8 heteroalkyl. 11. A method according to claim 5, wherein R.sup.4 is C.sub.3-C.sub.8 heteroalkyl. 12. A method according to claim 1, further comprising administering to the subject an anti-cancer agent. 13. A method according to claim 12, wherein the anti-cancer agent is selected from the group consisting of a conventional chemotherapeutic agent, a targeted therapeutic agent, a radiotherapeutic agent and a mixture thereof. 14. A method according to claim 12, wherein the anti-cancer agent is selected from the group consisting of cisplatin, oxaliplatin, carboplatin, erlotinib, gefitinib, lapatinib, cetuximab, zalutumumab, minotuzumab, and matuzumab. 15. A method according to claim 1, wherein administering the composition is conducted orally. 16. A method according to claim 1, wherein administering the composition is conducted parenterally. 17. A method according to claim 1, wherein the compound has the formula: ##STR00114## or a pharmaceutically acceptable salt thereof. 18. A method according to claim 1, wherein the compound has the formula: ##STR00115## or a pharmaceutically acceptable salt thereof. 19. A method according to claim 1, wherein the compound has the formula: ##STR00116## or a pharmaceutically acceptable salt thereof. 20. A method according to claim 1, wherein the compound has the formula: ##STR00117## or a pharmaceutically acceptable salt thereof.

Details for Patent 9,540,410

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2032-11-13
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2032-11-13